ACOU085 – lessons learned from developing a locally administered otoprotectant
Dr Jonas Dhyrfjeld-Johnsen, Acousia Therapeutics
Key considerations for developing a clinically relevant formulation for local administration and obtaining relevant inner ear exposures
Choice of species for local admininstration toxicology studies
Clinical Phase 1b recruitment complexity, key learnings for Phase 2.
About Dr Jonas Dhyrfjeld-Johnsen
Chief Development Officer, Acousia Therapeutics, Germany
As Chief Development Officer of Acousia Therapeutics, Jonas Dhyrfjeld-Johnsen is responsible for the company’s research and preclinical/non-clinical/translational strategy development, implementation, and execution.
Jonas has broad experience in inner ear and CNS research and drug development previously serving as Head of Pharmacology of the remyelination biotech ReWind Therapeutics and having held several positions in preclinical and translational development at Sensorion (latest as VP of Research and Translational Development), where he guided two inner ear candidate drugs from early preclinical development into phase 2 clinical trials.
He received his PhD in Neuroscience from the Heinrich-Heine University in Düsseldorf (Germany) after an MSc in Biophysics from the University of Copenhagen (Denmark) with postdoctoral training at the University of California – Irvine and Harvard Medical School/Massachusetts General Hospital in Boston (USA).
Satellite event of the 58th Inner Ear Biology Meeting
